NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $57.92, signifying a +0.61% move from its prior day's close.
CRISPR Therapeutics AG (CRSP) closed at $57.19 in the latest trading session, marking a +1.69% move from the prior day.
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby ope

3 Monster Stocks in the Making to Buy Right Now

06:00am, Saturday, 20'th Jul 2024
CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.

3 Gene Editing Stocks That Could Grow Your Wealth

01:30pm, Wednesday, 17'th Jul 2024
Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology.  Examples include CRISPR and other gene-editing technologies.

Add These 5 Hot Biotech Stocks In July

09:22am, Wednesday, 17'th Jul 2024
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dolla
CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps i
CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organism
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE